New York, Jan 28, 2026, 09:22 EST — Premarket
- BIO-key shares surge in premarket following announcement of a Portugal municipal deal linked to Visualforma
- The company aims to deploy its solution across over 250 public-sector organizations in Portugal; financial details were not revealed
- Investors are also watching BKYI’s Nasdaq $1 bid-price compliance clock closely
Shares of BIO-key International Inc surged roughly 36% in premarket trading Wednesday, climbing to around $0.74. The jump followed the company’s announcement of a new public-sector contract in Portugal. BKYI closed Tuesday near $0.55.
The company announced that its Visualforma partnership is kicking off a new business line targeting Portuguese municipal councils, with plans to expand throughout Portugal’s public sector. For such a lightly traded microcap, landing even a single overseas deal can shake up the day’s trading—at least at the open.
The timing is crucial for another reason: BKYI is still well under Nasdaq’s $1 minimum bid-price rule. A recent company filing reveals it has until May 4, 2026, to get back in line or risk delisting procedures. That same filing notes BIO-key has informed Nasdaq it might pursue a reverse stock split if necessary.
BIO-key announced that Visualforma, a Portuguese technology integrator, will handle deployment of its identity and biometric solutions across more than 250 government bodies, including municipal administrations, education, and healthcare sectors. Humberto Bento, Visualforma’s operations director, described the move as “a strategic step” in advancing municipal digital transformation. BIO-key managing director Alex Rocha emphasized their goal of putting “security, trust, and ease of use” at the heart of municipal services. GlobeNewswire
The company is marketing the solution as Identity and Access Management, or IAM — software that controls who can access which systems and when — combined with biometric verification. It features multi-factor authentication (MFA), requiring more than just a password, and single sign-on (SSO), allowing users to log into several systems with a single credential.
IAM is a crowded field, dominated by bigger players like Okta and CyberArk offering access-control solutions to enterprises. BIO-key, however, focuses on a narrower niche: biometrics-centric logins and public-sector rollouts via local partners.
Traders will be keeping an eye on how much of the premarket surge holds up as regular trading kicks off, when spreads typically narrow and volume picks up. Given the stock’s low share price, even modest dollar moves can swing BKYI’s price noticeably.
There are clear unknowns. The company hasn’t revealed the financial details, and public-sector projects often drag on—particularly when they involve citizen services and compliance. A marquee contract doesn’t necessarily mean revenue will show up right away.
Next on the docket is the open and any subsequent updates on timing and scope, including whether BIO-key provides specific figures on the project in a filing. Looking ahead, the key trigger is the Nasdaq bid-price clock — investors will be watching to see if BKYI can stay above $1 for 10 straight sessions ahead of the May 4 deadline.
